• Je něco špatně v tomto záznamu ?

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors

A. Űrgeová, M. Javorský, L. Klimčáková, J. Židzik, J. Šalagovič, JA. Hubáček, P. Doubravová, I. Gotthardová, M. Kvapil, T. Pelikánová, I. Tkáč, AS. Yaluri

. 2020 ; 21 (5) : 317-323. [pub] 20200420

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001339
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2000-02-01 do 2020-12-31
Health & Medicine (ProQuest) od 2000-02-01 do 2020-12-31

Odkazy

PubMed 32308134
DOI 10.2217/pgs-2019-0147
Knihovny.cz E-zdroje

Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment with DPP4 inhibitors. Patients & methods: 206 patients with type 2 diabetes (116 men and 90 women) were treated with sitagliptin or vildagliptin (both 100 mg/day) in combination with metformin or metformin/sulphonylurea over 6 months, and the reduction in glycated hemoglobin (HbA1c) was measured. Results: Rs6923761 in GLP1R was significantly associated with a reduction in HbA1c (adjusted p = 0.006). Homozygotes for the minor A allele had smaller reduction in HbA1c by 0.4% (4 mmol/mol) than the G allele carriers (p = 0.016). Conclusion: The missense variant rs6923761 in the GLP1R gene was associated with a smaller glycemic response to 6 month gliptin therapy in diabetic patients of central European origin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001339
003      
CZ-PrNML
005      
20240213094549.0
007      
ta
008      
240109s2020 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/pgs-2019-0147 $2 doi
035    __
$a (PubMed)32308134
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Űrgeová, Anna $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia $u Louis. Pasteur University Hospital, Košice, Slovakia
245    10
$a Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors / $c A. Űrgeová, M. Javorský, L. Klimčáková, J. Židzik, J. Šalagovič, JA. Hubáček, P. Doubravová, I. Gotthardová, M. Kvapil, T. Pelikánová, I. Tkáč, AS. Yaluri
520    9_
$a Aim: We examined associations of eight SNPs in/near seven candidate genes with glycemic response to 6 month treatment with DPP4 inhibitors. Patients & methods: 206 patients with type 2 diabetes (116 men and 90 women) were treated with sitagliptin or vildagliptin (both 100 mg/day) in combination with metformin or metformin/sulphonylurea over 6 months, and the reduction in glycated hemoglobin (HbA1c) was measured. Results: Rs6923761 in GLP1R was significantly associated with a reduction in HbA1c (adjusted p = 0.006). Homozygotes for the minor A allele had smaller reduction in HbA1c by 0.4% (4 mmol/mol) than the G allele carriers (p = 0.016). Conclusion: The missense variant rs6923761 in the GLP1R gene was associated with a smaller glycemic response to 6 month gliptin therapy in diabetic patients of central European origin.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a inhibitory dipeptidylpeptidasy 4 $x terapeutické užití $7 D054873
650    12
$a diabetes mellitus 2. typu $x farmakoterapie $x genetika $7 D003924
650    _2
$a vildagliptin $x terapeutické užití $7 D000077597
650    _2
$a alely $7 D000483
650    12
$a metformin $7 D008687
655    _2
$a časopisecké články $7 D016428
700    1_
$a Javorský, Martin $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia $u Louis. Pasteur University Hospital, Košice, Slovakia
700    1_
$a Klimčáková, Lucia $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia
700    1_
$a Židzik, Jozef $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia
700    1_
$a Šalagovič, Ján $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia
700    1_
$a Hubáček, Jaroslav A $u Institute for Clinical & Experimental Medicine, Prague, Czech Republic
700    1_
$a Doubravová, Pavlina $u Faculty Hospital in Motol, Department of Medicine, Prague, Czech Republic
700    1_
$a Gotthardová, Ivana $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia $u Louis. Pasteur University Hospital, Košice, Slovakia
700    1_
$a Kvapil, Milan $u Charles University, Faculty of Medicine 2, Prague, Czech Republic $u Faculty Hospital in Motol, Department of Medicine, Prague, Czech Republic
700    1_
$a Pelikánová, Terezie $u Institute for Clinical & Experimental Medicine, Diabetes Centre, Prague, Czech Republic
700    1_
$a Tkáč, Ivan $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia $u Louis. Pasteur University Hospital, Košice, Slovakia
700    1_
$a Yaluri, Alena Stančáková $u Pavol Jozef Šafárik University, Faculty of Medicine, Košice, Slovakia $u Louis. Pasteur University Hospital, Košice, Slovakia $1 https://orcid.org/0000000213750252
773    0_
$w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 21, č. 5 (2020), s. 317-323
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32308134 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094546 $b ABA008
999    __
$a ok $b bmc $g 2049771 $s 1211033
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2020 $b 21 $c 5 $d 317-323 $e 20200420 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace